hotspot -WSS

hotspot

author：comprehensive 2025-09-30 18:17:46 - browse：57472

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： New oral drug delivery patch is modeled after octopus tentacles

WSS

Flu, Covid vaccination rates decline, new survey data show

Elizabeth Holmes banned from government health programs

What will Novo Nordisk's VC do with its influx of cash?

Stop Congress from blocking public access to science

European officials brace for rough respiratory virus season

European officials brace for rough respiratory virus season

hotspot

hotspot

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

EU regulator recommends expanding Mounjaro approval to obesity

Wildfire smoke exposes gaps in outdoor worker protections

Stop Congress from blocking public access to science

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What will Novo Nordisk's VC do with its influx of cash?

After affirmative action ruling, medical educators look to 'holistic review'

New brain studies show LSD's effects on the brain in full color

Malaria cases in Florida and Texas: Here’s what you need to know

Biotech venture capitalists face new demands from investors

leisure time

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

NIH director takes cautious approach to Biden drug pricing priority

Francis Collins on trust in science and how Covid communications failed

Humana cuts profit projections as Medicare Advantage costs soar

Humana cuts profit projections as Medicare Advantage costs soar

Humana cuts profit projections as Medicare Advantage costs soar

focus

leisure time

leisure time

entertainment